Table 4

Multivariable analyses on the risk of incident CRC in relation to subsequent FIT with different time windows and other factors

Crude HR (95% CI)Adjusted HR (95% CI)
Model 1Model 2
Age1.02 (0.99 to 1.06)1.00 (0.96 to 1.03)1.00 (0.96 to 1.03)
Gender
 Male vs female1.37 (0.93 to 2.01)1.23 (0.83 to 1.81)1.23 (0.84 to 1.81)
Subsequent FIT
 No1Ref1
 Yes0.44 (0.30 to 0.64)0.47 (0.31 to 0.71)
 1.5–3 years0.48 (0.29 to 0.77)0.53 (0.32 to 0.88)
 3–5 years0.43 (0.25 to 0.74)0.45 (0.26 to 0.79)
 >5 years0.36 (0.18 to 0.74)0.37 (0.18 to 0.77)
Adenoma detection rate
 >49%Refrefref
 42%–49%1.66 (1.01 to 2.72)1.42 (0.86 to 2.34)1.47 (0.89 to 2.43)
 <42%1.96 (1.19 to 3.23)1.61 (0.97 to 2.67)1.66 (1.00 to 2.77)
FHbC of baseline FIT (μg hemoglobin/g faeces)
 20–39RefRefRef
 40–591.98 (1.07 to 3.66)1.94 (1.05 to 3.58)1.93 (1.04 to 3.56)
 60–991.00 (0.47 to 2.11)0.95 (0.45 to 2.01)0.95 (0.45 to 2.00)
 100–1492.40 (1.23 to 4.70)2.28 (1.17 to 4.46)2.26 (1.16 to 4.43)
 ≥1502.59 (1.54 to 4.37)2.46 (1.45 to 4.15)2.44 (1.44 to 4.12)
CRC family history in first-degree relatives
 NoRef
 Yes1.11 (0.27 to 4.50)
FIT kit
 HM-JACKRef
 OC-Sensor1.15 (0.63 to 2.10)
  • CRC, colorectal cancer; FHbC, faecal haemoglobin concentration; ; FIT, faecal immunochemical test.